Archive · 29 Nov 2025
Ajanta Pharma: Strong Growth but High Valuations
Ajanta Pharma is growing well in many places like India, the US, Asia, and Africa.
They sell medicines and have been doing really well, especially in areas like heart health, skin care, and eye care.
They are also adding new types of medicines and more salespeople to help them grow.
However, their stock is quite expensive now, which might make it harder to grow even more.
They are still making good money, but some parts of their business make less money than others.
Investors should be careful because the stock might not grow as much in the future because it's already quite expensive.
Ajanta Pharma shows strong growth in India, US, Asia, and Africa.
Stock has returned 78% since June 2023 but trades at 28 times forward earnings.
EBITDA margins have slightly decreased to 26% in H1-FY26, targeting 27 ±1% for FY26.
US generics business grew 42% year-on-year in H1-FY26 with 8-10 new launches annually.
Company is expanding sales force and entering new therapy areas to sustain growth.
- Who
- Ajanta Pharma
- What
- Strong growth in India, US, Asia, and Africa with high valuations
- When
- June 2023 to present
- Where
- India, US, Asia, Africa
- Why
- Strong business outlook but high valuations limit growth potential
- Current Valuation
- 28 times one-year forward earnings
- EBITDA Margin (H1-FY26)
- 26%
- EBITDA Margin Target (FY26)
- 27 ±1%
- US Revenue Growth (H1-FY26)
- 42% year-on-year
- Medical Representatives (India)
- 3,600 in FY25, adding 100 more
- New Therapy Areas (India)
- Gynaecology and Nephrology
- Growth in Asia and Africa (FY20-25)
- 13% CAGR
- Stock Return (June 2023 to Present)
- 78%